The Use of Prostate-Specific Antigen in Staging Patients With Newly Diagnosed Prostate Cancer

摘要: Objective. —To assess the need for obtaining radionuclide bone scans in staging evaluation of patients with newly diagnosed, untreated prostate cancer. This determination was made on basis presenting prostate-specific antigen (PSA) levels. Design. —Retrospective review. Participants. —The medical records 2064 consecutive cancer who were evaluated at Mayo Clinic Rochester, Minn, from January 1989 through December 1990 reviewed. Eight hundred fifty-two disease and a serum PSA concentration less than 20.0 μg/L presentation comprised study population. Main Outcome Measure. rate false-negative results associated using to predict scan findings. Results. —Five sixty-one had 10.0 or less; only three an abnormal result, one indeterminate result. Of 467 men whose value 8.0 (two times upper limit reference range), none that either indeterminate. The result 0% 0.5% cutoff level μg/L. 95% confidence all levels 2%. Conclusions. —For cancer, less, no skeletal symptoms, does not appear be necessary. clinical situation applies 39% diagnosed Since more 130 000 new cases are each year, approximately 50 affected annually. If $600 eliminated these patients, significant economic savings health care system this country would effected. ( JAMA . 1993;269:57-60)